associate sponsors

Llyod
HDFC

Zydus Group clinches in-licensing deal with Swiss co Neovii to market Grafalon drug

New Delhi: Ahmedabad-based Zydus Group has got into an in-licensing agreement with Switzerland-based Neovii to launch Grafalon, an immunosuppressant used in solid organ transplants and stem cell transplant, in India.

Reuters

Reuters

"The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine," group firm Cadila Healthcare said in a filing to BSE.

Grafalon offers a specific advantage of efficacy and better safety profile through targeted immunosuppression, it added.

"More than 200,000 patients till date, in over 50 countries, have been treated with Grafalon," Cadila Healthcare said. Transplant outcomes can be improved significantly by the use of immunosuppressant drugs like Grafalon, it added.

"Currently, an estimated 10,000 solid organ transplant and stem cell transplants are taking place annually across 200 plus transplant centres in India," the company said.

The stock of Cadila Healthcare was today trading at Rs 386.50 in the afternoon trade on BSE, down 0.54 per cent from its previous close.


Updated Date: Oct 06, 2016 15:47 PM

Also Watch

Watch: The true stories from Dharavi that inspired Rajinikanth's Kaala
  • Thursday, March 8, 2018 Watch: Cyrus Khan talks about Parkour, jumping across walls and why he hates sitting
  • Thursday, May 31, 2018 Unwind: India's basketball sensation Amjyot Singh has his eyes set on becoming an NBA regular
  • Monday, May 28, 2018 First Day First Showsha — Review of Solo: A Star Wars Story in 10 questions
  • Saturday, May 19, 2018 Social Media Star: Rajkummar Rao and Bhuvan Bam open up about selfie culture, online trolls

Also See